DAIICHI SANKYO, INC.

Hiroyuki Okuzawa assumed leadership of Daiichi Sankyo two months ago, inheriting a company strengthened by three major pharmaceutical licensing deals worth up to $27 billion based on ADC technology.

The phase II TUXEDO-3 trial showed patritumab deruxtecan (HER3-DXd) achieved intracranial response rates of 23.8% in metastatic breast cancer and 30% in advanced non-small cell lung cancer patients with active brain metastases.

A multi-institutional study of 1,476 patients found that 75% of those with grade 1 interstitial lung disease (ILD) were successfully rechallenged with trastuzumab deruxtecan, remaining on therapy for a median of 215 days.

Merck KGaA's antibody-drug conjugate precemtabart tocentecan demonstrated safety and tolerability in a Phase Ib trial for metastatic colorectal cancer patients.

Merck and Daiichi Sankyo withdrew their FDA application for patritumab deruxtecan, an antibody-drug conjugate targeting EGFR-mutated non-small cell lung cancer, after the drug failed to demonstrate overall survival benefit.

Daiichi Sankyo and Merck voluntarily withdrew their Biologics License Application for patritumab deruxtecan in EGFR-mutated NSCLC after the confirmatory HERTHENA-Lung02 Phase 3 trial failed to demonstrate statistically significant overall survival benefit.

The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.

The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.

Canada's Drug Agency has issued a Time-Limited Reimbursement recommendation for ENHERTU (trastuzumab deruxtecan), marking the first such approval for HER2-positive gastric cancer patients.

ENHERTU combined with pertuzumab demonstrated superior progression-free survival compared to standard taxane, trastuzumab and pertuzumab therapy as first-line treatment for HER2 positive metastatic breast cancer in the DESTINY-Breast09 phase 3 trial.